MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.460
+0.220
+17.74%
After Hours: 1.460 0 0.00% 17:26 04/08 EDT
OPEN
1.700
PREV CLOSE
1.240
HIGH
1.710
LOW
1.380
VOLUME
997.96K
TURNOVER
--
52 WEEK HIGH
4.190
52 WEEK LOW
0.8130
MARKET CAP
44.69M
P/E (TTM)
-0.4979
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IDRA stock price target is 8.20 with a high estimate of 10.00 and a low estimate of 5.00.

EPS

IDRA News

More
  • The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO
  • Benzinga · 17h ago
  • Idera jumps 39% after hours on bullish capital raise
  • seekingalpha · 1d ago
  • Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million
  • GlobeNewswire · 1d ago
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 03/25 17:54

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About IDRA

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
More

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.